Navigation Links
Bionovo Announces $5 Million Financing
Date:1/3/2012

EMERYVILLE, Calif., Jan. 3, 2012 /PRNewswire/ -- Bionovo, Inc. (NASDAQ: BNVI), a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, today announced that it has entered into a $5 million securities purchase agreement with Socius CG II, Ltd. ("Socius"), a Bermuda-based subsidiary of Socius Capital Group, LLC.

(Logo: http://photos.prnewswire.com/prnh/20111110/SF04662LOGO)

"In a challenging economic environment, we are pleased to have the necessary financial resources to continue the development of our drug candidate, Menerba," stated Isaac Cohen, OMD, Bionovo's chairman and CEO. "With this funding, we will continue the phase 3 clinical trial for Menerba, our drug candidate for the treatment of menopausal hot flashes. We also will be able to continue discussions with strategic partners to provide a stronger financial base."

Under the terms of the agreement, the Company has the right, in its sole discretion, over a term of two (2) years and subject to certain closing conditions and limitations, to sell to Socius up to a total of $5 million of redeemable Series A Preferred Stock of the Company (the "Preferred Stock"), payable in tranches. The Preferred Stock will accrue a 10% dividend per annum from the date of issuance. Pursuant to the purchase agreement, in addition to the Preferred Stock, Socius shall receive warrants to purchase shares of the Company's common stock valued at 35% of the Preferred Stock amount.  The exercise price of the warrants will equal the closing bid price of the Company's common stock on the preceding day.

When Preferred Stock is sold, Socius is also obligated to exercise an additional investment right to purchase a number of shares of common stock valued at 100% of the amount o
'/>"/>

SOURCE Bionovo, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Bionovo Announces Closing of Follow-on Offering of Common Stock and Warrants
2. Bionovo, Inc. to Announce First Quarter Fiscal Year 2010 Financial Results on Tuesday, May 11, 2010
3. Bionovo Announces Publication Describing First Novel Dual mTOR Inhibitor, BN107, for the Treatment of Breast Cancer
4. Bionovo to Present on Novel Female-Specific Drugs for Obesity at the 20th Annual Meeting of the North American Menopause Society
5. Bionovo, Inc. to Announce Second Quarter Fiscal Year 2009 Financial Results on Monday, August 10, 2009
6. Bionovo Appoints Dr. Klaus Kohl as Chief Technical Officer
7. Bionovo Announces Publication of Data on Active Compound and Mechanism of Action for Its Preclinical Cancer Treatment, BN108
8. Bionovo Announces 2008 Highlights and Year-End Financial Results
9. Bionovo Announces Publication of Positive Phase 2 Trial Results for Menerba(TM)
10. Bert W. OMalley, M.D., Recipient of the 2008 National Medal for Science, Joins Bionovos Scientific Advisory Board
11. Bionovo Publishes Discoveries in Predictable Tissue Selectivity for Selective Estrogen Receptor Modulators Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... DUBLIN , Aug. 27, 2014 ... the "Global Enzyme for Pulp & Paper Industry ... The Global Enzyme for Pulp & Paper Industry ... the current state of the global enzyme for pulp ... basic overview of the industry including definitions, classifications, applications ...
(Date:8/27/2014)... BIOEQUA, an innovative line of skin care ... handheld spray, has made its EQUA ESSENTIAL line available ... brand began with an unexpected discovery in an emergency ... that the application of nanospray technology allowed for liquid ... to skin's basal layer. This resulted in immediate absorption ...
(Date:8/27/2014)... 27, 2014 Budding Biomedical Scientists ... University School participated in the Scientific Enrichment ... University’s School of Medicine . , ... unparalleled professional experience in the sciences and brings ... faculty and students for both academic and career ...
(Date:8/26/2014)... The 20 ambassadors representing the ALS Therapy Development ... following statement on Facebook today regarding the global Ice ... specifically for ALS research: , “Who would have thought ... raise all this awareness and funding toward ALS research! ... of the entire ALS community, would like to express ...
Breaking Biology Technology:Global Enzyme for Pulp & Paper Industry Report 2014 2BIOEQUA'S EQUA ESSENTIAL Product Line Redefines Skin Care & Now Available in America 2Students at Cleveland's University School Conduct Biomedical Research at Case Western Reserve University’s School of Medicine 2ALS TDI’s Young Faces of ALS Ambassadors Thank You for Accepting the Ice Bucket Challenge to End ALS 2ALS TDI’s Young Faces of ALS Ambassadors Thank You for Accepting the Ice Bucket Challenge to End ALS 3ALS TDI’s Young Faces of ALS Ambassadors Thank You for Accepting the Ice Bucket Challenge to End ALS 4
... 24, 2011 Champions Biotechnology, Inc. (OTC: CSBR) ... collaboration agreement with Cephalon, Inc. in which Champions ... proprietary chemical compounds, CEP-32496, an inhibitor of mutant ... provided by Cephalon to determine the activity or ...
... ValGenesis, Inc., an industry-leading provider of Validation ... availability of its industry-proven solution as an On-Demand ... MUSA,s Validated Cloud. ValGenesis On-Demand provides ... via the Internet through MUSA,s Validated Cloud on ...
... Medicine, Inc. (RBM), a leading provider of innovative biomarker ... ® , a powerful tool developed at the direction ... Through quantitative measurement of 101 cancer-related proteins, OncologyMAP ... biological pathways that could hold the key to understanding ...
Cached Biology Technology:Champions Announces Technology Collaboration Utilizing Champions' Tumorgraft™ Technology Platform for Oncology Drug Development 2Champions Announces Technology Collaboration Utilizing Champions' Tumorgraft™ Technology Platform for Oncology Drug Development 3Announcing ValGenesis On-Demand SaaS Solution 2Announcing ValGenesis On-Demand SaaS Solution 3Rules-Based Medicine Launches OncologyMAP® to Advance Cancer-Related Drug and Diagnostic Development 2
(Date:8/27/2014)... that exists as five strains, none of which have ... the Sudan ebolavirus (SUDV). Although not the strain currently ... as recently as 2012. In a new study appearing ... now report a possible therapy that could someday help ... Sidhu, Jonathan Lai and colleagues explain that about 50-90 ...
(Date:8/27/2014)... the long-standing belief that a deficiency in serotonin ... central role in depression. In the journal ACS ... ability to make serotonin in their brains (and thus ... show depression-like symptoms. , Donald Kuhn and colleagues ... Wayne State University School of Medicine note that depression ...
(Date:8/27/2014)... each year in U.S. waters and become what are ... crabs, and other species such as turtles. These traps ... who depend on the resources--losses that are largely preventable, ... report, published in the Marine Pollution Bulletin , ... derelict fish trap problem, and so-called "ghost fishing," nationally, ...
Breaking Biology News(10 mins):Potential therapy for the Sudan strain of Ebola could help contain some future outbreaks 2New study throws into question long-held belief about depression 2NOAA's Marine Debris Program reports on the national issue of derelict fishing traps 2
... as current directions and water temperature play a huge ... as they move from rivers and hit ocean waters ... findings inform restoration policies and practices focused on boosting ... findings, from ecologists at the Department of Energy,s Pacific ...
... The National Science Foundation (NSF), in cooperation with ... round of awards under a program that supports ... predictability, resiliency and sustainability of the natural and ... governance of the Arctic. Six projects ...
... international team of researchers says in a new paper ... realm more practical applications for dealing with the ... already exists as does much of the organizational structure, ... ranging from declining snowpack, to severe storms, to sea ...
Cached Biology News:Tracking young salmon's first moves in the ocean 2Tracking young salmon's first moves in the ocean 3Tracking young salmon's first moves in the ocean 4NSF, with interagency and international partners, makes first round of grants to understand Arctic sustainability 2NSF, with interagency and international partners, makes first round of grants to understand Arctic sustainability 3NSF, with interagency and international partners, makes first round of grants to understand Arctic sustainability 4NSF, with interagency and international partners, makes first round of grants to understand Arctic sustainability 5NSF, with interagency and international partners, makes first round of grants to understand Arctic sustainability 6Researchers advocate for climate adaptation science 2Researchers advocate for climate adaptation science 3
Reported to support murine B lymphocytes, hematopoietic tissue from bone marrow, B cells stimulated with lipopolysaccharide, T lymphocytes, and a variety of hybrid cells....
... Applied Biosystems and MDS Sciex ... System, a high performance hybrid triple ... the drug discovery, drug development or ... (LIT) Technology from the leaders in ...
... Many modifications of Eagle's ... the original formulation. The most ... Modified Eagle's,Medium. DME is a ... Eagle [MEM] that contains a ...
... isotonic, balanced salt solution. It is routinely used ... of whole blood at refrigerator temperatures for approximately ... blood is collected into a container of this ... is placed in a refrigerator at 2-8 C ...
Biology Products: